Literature DB >> 20878108

Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo.

Yu-Qing Wu1, Zheng Song, Cheng-Hua Zhou, Shu-Hua Xing, Dong-Sheng Pei, Jun-Nian Zheng.   

Abstract

Urotensin II (UII), originally identified from fish urophysis, is a potent vasoactive peptide and an endogenous ligand for an orphan G protein-coupled receptor GPR14, now named as urotensin II receptor (UT-R). In this study, we investigated the mRNA and protein expressions of UII and its receptor (UT-R) in human lung adenocarcinoma A549 cells, and the effect of exogenous UII on the proliferation of A549 cells in vitro and in vivo. Reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis showed that both mRNAs and proteins of UII and UT-R were obviously expressed in human lung adenocarcinoma A549 cells. Immunohistochemical analysis showed that UII peptide was mainly expressed in the cyto-plasm, and UT-R protein was expressed on the cytomembrane and also in the cytoplasm. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) analysis demonstrated that treatment with different concentrations of human UII (10(-9), 10(-8), 10(-7) and 10(-6) M) for 48 h significantly increased the number of A549 cells. The effect of UII at the concentration of 10(-7) M on the proliferation of A549 cells is most pronounced. Nude mice bearing human lung adenocarcinoma A549 cells treated with UII showed a significant increase in tumor volume and tumor weight compared with control group. These findings suggest that UII may contribute to the pathogenesis of human lung adenocarcinoma as an autocrine/paracrine growth stimulating factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878108     DOI: 10.3892/or_00000970

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway.

Authors:  Wei-Xi Zhang; Ya-Feng Liang; Xiao-Ming Wang; Ying Nie; Lei Chong; Li Lin; Chun Chen; Chang-Chong Li
Journal:  Mol Cell Biochem       Date:  2012-01-21       Impact factor: 3.396

2.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

3.  Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice.

Authors:  Cheng-Hua Zhou; Ya-Ya Wan; Xiang-Hua Chu; Zheng Song; Shu-Hua Xing; Yu-Qing Wu; Xiao-Xing Yin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

4.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

5.  Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients.

Authors:  Hongtao Wei; Xiaotong Yu; Xiaowei Xue; Hui Liu; Menglong Wang; Yingying Li; Xuejiang Wang; Huiguo Ding
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

Review 6.  The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features.

Authors:  Hélène Castel; Laurence Desrues; Jane-Eileen Joubert; Marie-Christine Tonon; Laurent Prézeau; Marie Chabbert; Fabrice Morin; Pierrick Gandolfo
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-25       Impact factor: 5.555

Review 7.  The Effect of Local Renin Angiotensin System in the Common Types of Cancer.

Authors:  Moudhi Almutlaq; Abir Abdullah Alamro; Hassan S Alamri; Amani Ahmed Alghamdi; Tlili Barhoumi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-03       Impact factor: 5.555

8.  Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER.

Authors:  Véronique Gigoux; Daniel Fourmy
Journal:  Front Endocrinol (Lausanne)       Date:  2013-04-29       Impact factor: 5.555

9.  Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Authors:  Benjamin Poret; Laurence Desrues; Marc-André Bonin; Martin Pédard; Martine Dubois; Richard Leduc; Romain Modzelewski; Pierre Decazes; Fabrice Morin; Pierre Vera; Hélène Castel; Pierre Bohn; Pierrick Gandolfo
Journal:  Biomolecules       Date:  2020-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.